Most anticancer therapies to date focus on druggable features of tumor epithelia. Despite the increasing repertoire of treatment options, patient responses remain varied. Moreover, tumor resistance and relapse remain persistent clinical challenges. These observations imply an incomplete understanding of tumor heterogeneity. The tumor microenvironment is a major determinant of disease progression and therapy outcome. Cancer-associated fibroblasts (CAFs) are the dominant cell type within the reactive stroma of tumors. They orchestrate paracrine pro-tumorigenic signaling with adjacent tumor cells, thus exacerbating the hallmarks of cancer and accelerating tumor malignancy. Although CAF-derived soluble factors have been investigated for tumor stromadirected therapy, the underlying transcriptional programs that enable the oncogenic functions of CAFs remain poorly understood. Nuclear receptors (NRs), a large family of ligand-responsive transcription factors, are pharmacologically viable targets for the suppression of CAF-facilitated oncogenesis. In this study, we defined the expression profiles of NRs in CAFs from clinical cutaneous squamous cell carcinoma (SCC) biopsies. We further identified a cluster of driver NRs in CAFs as important modifiers of CAF function with profound influence on cancer cell invasiveness, proliferation, drug resistance, energy metabolism and oxidative stress status. Importantly, guided by the NR profile of CAFs, retinoic acid receptor β and androgen receptor antagonists were identified for concurrent therapy with cisplatin, resulting in the inhibition of chemoresistance in recurred SCC:CAF xenografts. Our work demonstrates that treatments targeting both the tumor epithelia and the surrounding CAFs can extend the efficacy of conventional chemotherapy.
INTRODUCTION
The tumor microenvironment consists of a variety of stromal cells and a fibrotic matrix that surround and support malignant epithelia. 1, 2 The interactions among the various components of the tumor microenvironment, mediated largely by cytokines and growth factors, are significant. Tumor epithelia can change the nature of the microenvironment, and conversely, the microenvironment can affect how a tumor grows and spreads. 3, 4 Furthermore, tumor stroma co-evolution further disrupts tissue organization, 5, 6 and the resultant loss of organ homeostasis creates a feed-forward reaction permissive to tumor aggressiveness and malignancy. 4, 7 Despite this, many conventional cancer treatments are designed around druggable features of tumor epithelia, ignoring the supportive role of stromal cells. The diversity of patient outcomes from such treatments not only suggests that rapid resistance occurs, but also highlights an incomplete understanding of the tumor microenvironment. 8, 9 As the most abundant cell population in the tumor stroma, cancer-associated fibroblasts (CAFs) are a potent source of growth factors, extracellular matrix components, matrix remodeling enzymes, inflammatory cytokines and reactive oxygen species (ROS). Hence, CAFs create a microenvironment that promotes proliferation, invasiveness, oxidative stress, aberrant metabolism, immune evasion and therapy resistance of tumors. Although CAFs have been well characterized by their expression of alpha-smooth muscle actin, 10 fibroblast (FIB) activation protein, 11 plateletderived growth factor receptors, 12 asporin 13 and collagen 11α1, 14 the underlying transcriptional programs enabling the pro-oncogenic functions of CAFs remain poorly understood. Moreover, whereas transcription factor signaling nodes control many cellular behaviors, most transcription factors cannot be directly modulated by chemical drugs, and are considered poor pharmacological targets. 15, 16 Nuclear hormone receptors (NRs) represent a unique class of transcription factors that regulate gene expression under the strict control of endogenous or synthetic ligands. 3, 17 In humans, the 48 known NRs play numerous roles in development, physiology and pathology. Thus, ligands of NRs have the potential to modulate the cytokine profile of CAFs, leading to tumor suppression or tumor sensitization to conventional chemotherapy. However, the expression of NRs in CAFs from squamous cell carcinoma (SCC) tumors is unknown, and their non-redundant roles in SCC progression and chemoresistance is unclear.
As the primary experimental system to explore CAF NR-directed therapy, we defined an NR profile for CAFs from patients diagnosed with cutaneous SCC. Guided by this expression profile, the genetic and pharmacological targeting of specific driver NRs in CAFs diminished SCC invasiveness, proliferation, drug resistance, energy metabolism and oxidative stress status. Furthermore, primary and recurred xenograft tumor growth was attenuated by a combination treatment with NR ligands and cisplatin, in part due to reduced chemoresistance. Our findings suggest that NRdirected ligands that have successfully treated other pathologies such as inflammation, dyslipidemia and diabetes, may be repurposed as concurrent treatments to conventional anticancer chemotherapeutics.
RESULTS

NRs are differentially expressed between CAFs and normal FIBs
Paired samples of CAFs and peri-tumoral FIBs from archived SCC biopsies (n = 10) were microdissected ( Figure 1a) . RNA was then extracted and profiled for the expression of NR transcripts. Among the 26 NR transcripts detected, 18 were upregulated (more than twofold), five remained unchanged and three were downregulated (more than twofold) in CAFs compared with FIBs. Thirteen of the 21 differentially expressed NRs were druggable targets ( Figure 1b ).
Peroxisome proliferator-activated receptor (PPAR) β expression was downregulated to the greatest extent in CAFs, followed by the vitamin D receptor (VDR) and the glucocorticoid receptor (GR). Notably, RXRα and RXRβ were upregulated in CAFs compared with FIBs. As RXRs form heterodimeric partners with many NRs, we stratified the 21 NRs according to whether they heterodimerized with the RXRs. Nine of these 21 NRs were heterodimeric partners of RXRs (excluding the RXRs themselves) (Figure 1b) .
To further study CAFs in vitro, we first confirmed whether the NR signature of SCC CAFs remains stable when CAFs are removed from their native environment for culture. To this end, we performed NR profiling on patient CAFs explanted from human SCC tumors. Explanted CAFs were subjected to FACS analysis to verify their expression of vimentin and alpha-smooth muscle actin (Supplementary Figure S1) . A highly similar NR profile was observed between the microdissected CAFs and the explanted CAFs (Figure 1b) , indicating that the NR profile of SCC CAFs is retained during in vitro culture.
The SCC transcriptome is modified by changes in the CAF NR profile We hypothesized that by disrupting the NR status in CAFs, their paracrine interaction with cancer cells becomes compromised, Figure 1 . NRs are differentially expressed between CAFs and normal FIBs. (a) Representative images of hematoxylin-and eosin-stained sections of archived patient SCC biopsies before (left) and after (right) laser capture microdissection. CAFs within the tumor stroma directly bordering tumor epithelia were selectively excised while excluding obvious immune or vascular structures. Scale bar: 1 cm. (b) Relative expression of detectable NR transcripts in CAFs derived from metastatic and non-metastatic patient SCC biopsies (n = 10), compared against expression levels in matched pairs of peri-normal FIBs by RT-qPCR (left). Profiling was repeated using CAFs explanted from human SCC tumors (n = 5) and cultured in vitro (right). Expression values in CAFs are relative to that in normal FIBs, The first column in the heatmap represents the expression of NRs from five different FIB controls. NRs that form heterodimers with retinoid X receptors (RXRs) are labeled in red, while those that form homodimers are labeled in blue. Superscript numbers distinguish NRs with known ligands (1) from orphan NRs (2). Color scales: green = downregulated, red = upregulated. 'N.D.' denotes that the gene was not detected by RT-qPCR.
leading to changes in the cancer cell transcriptome that inhibit SCC aggressiveness. Guided by the NR profile of SCC CAFs, the individual knockdown or overexpression of specific NRs in CAFs was performed. Briefly, if the expression of an NR was downregulated in CAFs relative to FIBs, that NR was overexpressed (NR-OE). Conversely, an NR that was highly expressed in CAFs relative to FIBs was subjected to siRNA knockdown (NR-KD). NR-OE or NR-KD was verified with RT-qPCR and immunoblot (Supplementary Fig S2) . NR-OE or NR-KD did not affect CAF viability (Supplementary Figure S3a) . NR-OE/KD-CAFs were subsequently co-cultured with the malignant A-5RT3 SCC cells for 48 h. The A-5RT3 cells were then isolated for RNA extraction and microarray analysis (Figure 2a) .
The microarray analysis highlighted 302 genes differentially expressed by 41.5-fold between the A-5RT3 cells from the A-5RT3:CAF and A-5RT3:FIB co-cultures (Figure 2b ). Using the Ingenuity Pathway Analysis software for deeper analysis, the ontology term 'Tumor morphology' was enriched (Po 0.024) and 'Cancer' was identified as the topmost-enriched pathology (P o 0.030).
Next, we identified molecular and cellular functions in A-5RT3 cells that were altered by co-culture with CAFs. 'Cellular movement' (P o0.029), 'Cell morphology' (P o0.024), 'Cellular Function and Maintenance' (P o0.024), 'Cellular Growth and Proliferation' (P o 0.027) and 'Cell Cycle' (P o0.024) were the most strongly associated gene functions (Figure 2c ). The top networks in our analysis included 'Organismal injury and abnormalities' (score = 37), 'Cancer' (score = 34), 'Cell death and survival' (score = 22), 'Cell movement, signaling and interaction' (score = 18) and 'Inflammation' (score = 15) (Figure 2d ), reflecting a wound-like environment created by co-culture with CAFs.
To understand how the individual KD/OE of NRs in CAFs affected the A-5RT3 transcriptome, the expression of these 302 genes was examined in all A-5RT3:NR-KD/OE-CAF co-cultures. Hierarchical clustering revealed two major clusters; Cluster A: PPARβ/δ-OE-CAFs, androgen receptor (AR)-KD-CAFs, GR-OE-CAFs, retinoic acid receptor (RARβ)-KD-CAFs, VDR-OE-CAFs, and Cluster B containing two sub-clusters, B1 and B2. Cluster B2 gene signatures were highly similar to that of A-5RT3:CAF co-culture, indicating a functional redundancy among these CAF NRs, that is, the disruption of their individual expression was mutually compensated, thus limiting their impact on the SCC transcriptome. Although Cluster B1 gene signatures differed from the A-5RT3:CAF gene signature, these NRs are orphan receptors, making them poor pharmacological targets. In contrast, Cluster A alterations to the NR status of CAFs clearly modified the transcriptome of A-5RT3 cells in co-culture; 70 genes were inversely regulated (that is, downregulated in A-5RT3 from Cluster A co-cultures as opposed to upregulated in A-5RT3:CAF co-culture) (Figure 2b ). Importantly, genes associated with tumor malignancy, such as hepatocyte growth factor (HGF), zinc-finger E-box-binding 1 (ZEB1), periostin (POSTN) and interleukin (IL)-6, were strongly upregulated in A-5RT3:CAF co-culture, whereas in A-5RT3 cells co-cultured with Cluster A NR-KD/OE-CAFs, these same genes were downregulated (Figures 2c and d) . Thus, the KD/OE of cluster A NRs in CAFs are likely to attenuate SCC malignancy.
Genetic modulation of the NR expression of CAFs inhibits SCC malignancy and reduces chemoresistance Based on the microarray analysis, the malignant SCC phenotypes of invasion, proliferation, drug resistance, energy and ROS metabolism were influenced by the CAF NR status, especially NRs belonging to Cluster A. We examined the invasiveness of A-5RT3 cells using the transwell invasion assay. FIBs, CAFs or NR-OE/KD-CAFs seeded in the lower chamber provided the chemotactic gradient. CAFs potentiated the invasiveness of A-5RT3 cells by twofold compared with FIBs. While RARβ-KD-CAFs did not significantly reduce A-5RT3 invasiveness, PPARβ/δ-OE-CAFs and VDR-OE-CAFs reduced A-5RT3 invasiveness by 75% and 50%, respectively, compared with A-5RT3:CAF co-culture. AR-KD-CAFs and GR-OE-CAFs also inhibited A-5RT3 cell invasion by 27.5% and 23.0%, respectively ( Figure 3a) .
Next, we examined the proliferation of A-5RT3 cells co-cultured with FIBs, CAFs and NR-OE/KD-CAFs. Bromodeoxyuridine incubation followed by FACS analysis revealed that A-5RT3:CAFs coculture had increased proliferation when compared with A-5RT3: FIB co-culture (53.4 ± 2.4% vs 33.5 ± 5.1% in S-phase, respectively) ( Figure 3b ). Except for GR-OE-CAFs, all other NR-OE/KD-CAFs inhibited A-5RT3 cell proliferation by ⩾ 14% (Figure 3b ).
Although cisplatin is common in SCC chemotherapy, drug resistance arises quickly. Our microarray analysis suggested that chemoresistance is reinforced by the tumor stroma. Conditioned medium (CM) from CAFs conferred chemoprotective effects on A-5RT3 tumor cells treated with cisplatin, demonstrated by a twofold increase in the IC 50 dose of cisplatin compared with A-5RT3 cells in FIB CM (FIB CM IC 50 : 19.8 μg/ml vs, CAF CM IC 50 : 39.7 μg/ml). IC 50 is defined as the cisplatin dose required to reduce A-5RT3 survival to 50% of the total cell population. GR-OE-CAF CM increased the IC 50 compared with CAF CM, whereas AR-KD-CAF CM did not significantly change the IC 50 . In contrast, VDR-OE-CAF CM abrogated CAF-mediated chemoresistance to the greatest extent (IC 50 : 11.2 μg/ml), followed by PPARβ/δ-OE-CAF CM (24.4 μg/ml) and RARβ-KD-CAF CM (27 μg/ml) (Figure 3c ).
Altered energy metabolism is another cancer hallmark. We observed that A-5RT3:CAF co-culture displayed a 60% increase in glucose uptake with a concomitant 40% elevation of adenylate energy charge compared with A-5RT3:FIB co-culture (Figures 3d and e). Although GR-OE-CAFs and RAR-KD-CAFs did not significantly reduce A-5RT3 cell glucose uptake and energy charge, PPARβ/δ-OE-, VDR-OE-and AR-KD-CAFs inhibited glucose uptake by up to 50% (Figure 3e ) and lowered the energy charge of the cocultured A-5RT3 cells (Figure 3e ). We also assessed ROS levels in our co-culture systems. A-5RT3:CAFs co-culture displayed a 40% increase in intracellular ROS production relative to A-5RT3:FIB coculture, evidence of exacerbated oxidative stress. ROS production in A-5RT3 cells was only attenuated by co-culture with VDR-OECAFs ( Figure 3f ). To consolidate the antitumor efficacy of targeting specific CAF NRs, we overlaid the multi-parametric data from A-5RT3:NR-OE/ KD-CAF co-cultures onto the data from A-5RT3:CAF and A-5RT3:FIB co-cultures ( Figure 3g ). We observed that CAFs potentiate all six aggressive behaviors of the co-cultured A-5RT3 cells (red line) compared with FIBs (green line). The attenuation of any of these six SCC behaviors by NR-OE/KD-CAFs is indicated by the black line approaching the green line. Our analysis suggests that PPARβ/δ, VDR and, to a lesser extent, AR and RARβ expression in CAFs elicit antitumor effects and reduce chemoresistance (Figure 3g ). Interestingly, PPARβ/δ-OE-CAFs and VDR-OE-CAFs both inhibited mitochondrial dysfunction in co-cultured A-5RT3 (Supplementary Figure S3c) , indicating that energy metabolism is important in CAF-mediated oncogenesis.
Finally, CM from the co-cultures was subjected to a multiplexed protein assay screening for 16 secreted pro-tumor factors. The paracrine signaling network between CAFs and SCC cells was indeed disrupted by the altered CAF NR status (Figure 3h ). HGF and VEGF-C levels in the CM were attenuated to the greatest extents by NR-OE/KD-CAFs compared with CAFs.
Collectively, these results demonstrate that the transcriptome of SCC cancer cells is sensitive to the NR status of CAFs and suggest that SCC hallmarks are inhibited because oncogenic tumor stroma crosstalk is compromised.
Pharmacological modulation of CAF NRs inhibits SCC malignancy and reduces chemoresistance in vitro The KD/OE of specific NRs in CAFs resulted in the simultaneous attenuation of several cancer hallmarks. To test CAF NR-directed therapy in an experimental preclinical setting, we selected small molecule agonists of PPARβ/δ (GW0742), VDR (EB1089) and GR (fluticasone propionate), or antagonists of RARβ (LE135) and AR (bicalutamide) for evaluation. We first assessed whether these ligands had intrinsic anticancer activity. A-5RT3 cells were treated with each ligand at 5 μM for 24 h and analyzed by FACS for bromodeoxyuridine uptake and Annexin-PI staining. The results showed that only EB1089, the VDR agonist, significantly reduced A-5RT3 proliferation and increased A-5RT3 apoptosis (Figures 4a  and b) . Using A431 cells, another cell line representative of cutaneous SCC, we observed that only EB1089 treatment inhibited A431 cell proliferation, while only LE135 treatment promoted apoptosis of A431 cells (Supplementary Figures S4a, b) .
To explore whether these NR ligands demonstrate anticancer properties via CAFs, we pre-treated CAFs with the ligands for 48 h. The CAFs were rinsed thoroughly to remove excess ligand, and fresh serum-free medium was added for conditioning. The 48-hour CM from pre-treated CAFs was collected and added to A-5RT3 cells. CAF CM potentiated A-5RT3 cell proliferation compared with FIBs CM. CM from GW0742 and fluticasone propionate pre-treated CAFs did not significantly alter A-5RT3 proliferation. Interestingly, A-5RT3 cells cultured in LE135 or bicalutamide pre-treated CAF CM showed reduced proliferation (Figure 4c ). This was not observed when A-5RT3 cells were directly exposed to the ligands, suggesting a CAF-dependent effect. In contrast, CM from EB1089 pre-treated CAFs did not have any antiproliferative effect, indicating that EB1089 acts directly on A-5RT3 cells to inhibit proliferation (Figure 4c ). For A431 cells, the CM of GW0742 treated CAFs promoted cell proliferation (Supplementary Figure S4c) . Notably, when the CM from the ligand-treated cocultures was subjected to a multiplexed protein assay screening for 8 secreted pro-tumor factors, the co-cultures treated with a combination of LE135 and bicalutamide displayed the strongest suppression of pro-tumor paracrine activity as compared with vehicle-treated controls (Supplementary Figure S5) .
Next, we explored whether our selected NR ligands could sensitize A-5RT3 cells to cisplatin. A-5RT3 cells were cultured in pre-treated CAF CM in the presence of 10 μg/ml cisplatin. Nearly 40% of A-5RT3 cells underwent apoptosis when cultured in FIB CM, compared with only 5% when cultured in CAF CM. Pretreating CAFs with LE135, bicalutamide or EB1089 abrogated the CAF-enabled resistant phenotype in A-5RT3 cells (Figure 4d ). On the other hand, we observed that the CM of CAFs pre-treated with the five NR ligands abrogated CAF-mediated chemoresistance to 5-fluorouracil in A431 cells, with LE135 pretreatment of CAFs exhibiting the most potent paracrine effect (Supplementary Figure S4d) .
In the earlier NR-KD/OE-CAF experiments, VDR and PPARβ/δ demonstrated potent anticancer properties. However, RARβ and AR appeared as better pharmacological targets for CAF-directed therapy. Therefore, we tested whether this discrepancy could be explained by the relative expression of the NRs in A-5RT3 cells and CAFs. RT-qPCR revealed that VDR expression was higher in A-5RT3 cells than in CAFs (Figure 4e ). Thus, A-5RT3 cells are more responsive to EB1089. Unlike VDR-OE-CAFs that demonstrated anticancer effects, pre-treating CAFs with EB1089 had limited impact because of the low endogenous expression of VDR. Conversely, RARβ and AR expression was much higher in CAFs than A-5RT3 cells (Figure 4e) . In A431 cells, AR and RARβ expression is also virtually absent (Supplementary Figure S4e) . Hence, the pretreatment of CAFs with RARβ and AR antagonists, which bind to the abundant levels of their cognate NRs in CAFs, resulted in a non-cell autonomous inhibition of SCC aggressiveness and chemoresistance (Figures 4c and d) . Collectively, our in vitro data suggest that LE135 and bicalutamide, and thus RARβ and AR, are potential NR candidates for CAF-directed therapy.
Cisplatin with LE135 and bicalutamide concurrent therapy inhibits SCC malignancy and reduces chemoresistance in vivo Based on in vitro data, a concurrent treatment using cisplatin with LE135 and/or bicalutamide was effective against SCC via CAFs. To test their efficacy in vivo, we first titrated the dose of cisplatin in immunodeficient NSG (NOD SCID gamma) mice bearing subcutaneous A-5RT3:CAF xenografts. An intraperitoneal dose of 2 mg/kg cisplatin administered twice (on weeks 3 and 4) was required to impede tumor growth (Supplementary Figure S5a) . Although 10 mg/kg cisplatin reduced the tumor volumes, it was accompanied by proteinuria (Supplementary Figure S6a, b) which indicates nephrotoxicity, a common side effect of cisplatin chemotherapy. Therefore, 2 mg/kg cisplatin in combination with 5 mg/kg LE135 18, 19 and 10 mg/kg bicalutamide 20, 21 was intraperitoneally administered twice on weeks 3 and 4. Cisplatin in combination with LE135 (CL) or bicalutamide (CB) did not significantly improve treatment outcome compared with cisplatin alone treatment (CV). Significant delay in tumor growth was observed only when both LE135 and bicalutamide were used concurrently with cisplatin (CBL). However, tumor remission, defined as a reduction in tumor volume, was not achieved (Figure 5a) .
Gelatin zymography and immunoblot analysis of tumor lysates revealed that the properties of the A-5RT3:CAF tumor xenografts were altered by the treatments. MMP2, PCNA and GLUT1 expression was significantly reduced only by CBL therapy, suggesting that the full combination of drugs was required to impair tumor invasiveness, proliferation and energy metabolism, respectively. Caspase 3 expression was also strongly elevated by the CL and CBL treatments (Figure 5b, Supplementary Figure S6c) . Immunofluorescence staining further showed that laminin 5 expression, which is inversely associated with tumor invasiveness, was only restored by CBL treatment (Figure 5c ). The staining of the epithelial marker, E-cad (E-cadherin), was more intense and defined at cell:cell boundaries upon CL, CB and CBL treatments compared with CV. The proliferation marker Ki67 was reduced by CL, CB and CBL treatment compared with CV. Moreover, terminal deoxynucleotidyltransferase dUTP nick end labeling assay (TUNEL) showed that the number of apoptotic tumor cells was increased only by CBL therapy, corresponding with increased intratumoral cisplatin:DNA adducts (Figure 5c ).
Despite the attenuation of tumor aggressiveness, tumor remission did not occur, likely owing to insufficient intratumoral accumulation of cisplatin. Furthermore, the inflection point at week 4 in the tumor growth curve suggested that cisplatin resistance was developing (Figure 5a) . Hence, the injection of cisplatin directly into tumors could improve treatment outcomes. As SCC tumors are located superficially, the intratumoral injection of cisplatin is feasible.
To assess the efficacy of this treatment route, we established tumor xenografts in another group of NSG mice. On weeks 3 and 4, when xenograft volumes approached 150 mm 3 , 2 mg/kg cisplatin was injected directly into the tumors, with 5 mg/kg LE135 and/or 10 mg/kg bicalutamide injected intraperitoneally as before, given their effect in earlier experiments. CL, CB and CBL treatments significantly reduced tumor volumes compared with CV treatment. Although treatment was discontinued beyond week 4, tumor remission was sustained until week 6. This suggested that the combined therapies had sensitized tumors to cisplatin.
To observe whether tumors would recur, the same mice were maintained even after tumors became impalpable (Figure 6a ). Tumors reappeared on week 7 for mice that received CV, CL and CB therapies. Tumor recurrence was also observed in CBL-treated mice on week 9, suggesting the presence of residual disease after the first round of combinatorial therapy. These results presented an opportunity to study whether the surviving A-5RT3:CAF tumors had developed resistance. The tumors were allowed to grow until tumor volumes approached 150 mm 3 before treatment was resumed (mice were treated on weeks 11 and 12). Recurred tumor xenografts resisted second-round CV and CB treatments; CL treatment impeded tumor growth without causing remission (Figure 6a) . Notably, tumor xenografts responded optimally to second-round CBL treatment, becoming barely palpable by week 14 (Figure 6a) .
Gelatin zymography analysis of tumor lysates revealed that MMP9 expression was strongly repressed by CL and CBL treatments. PCNA and GLUT1 protein expression was only reduced by CBL treatment. Meanwhile, caspase 3 protein expression was upregulated fourfold, threefold and 4100-fold by CL, CB and CBL treatments, respectively, compared with CV treatment (Figure 6b,  Supplementary Figure S6d) . Immunofluorescence staining also showed that CBL therapy was most effective in restoring laminin 5 expression, accompanied by intense and well-defined E-cad staining, reduced Ki67 staining and increased number of TUNELpositive nuclei (Figure 6c) . Importantly, the numerous cisplatin: DNA adducts in CBL-treated tumors suggested that CBL therapy played a role in reducing chemoresistance.
Finally, gelatin zymography, immunoblot (PCNA, GLUT1 and caspase 3) and immunofluorescence (cisplatin adducts) data representing SCC tumor invasiveness, proliferation, energy metabolism, apoptosis and cisplatin sensitivity, respectively, were consolidated into a multi-parametric chart of treatment efficacy. The red line represents tumor response to CV treatment which forms the baseline for comparison (Figure 6d ). The green line represents tumor response to CL, CB or CBL therapy. Our data suggest that RARβ and AR antagonists are effective when concurrently administered with cisplatin chemotherapy.
To validate the efficacy of NR antagonists as an adjunctive treatment alongside another chemotherapy drug commonly used in SCC, we treated mice bearing A431:CAF tumor xenografts with 10mg/kg of 5-fluorouracil alone (FV) or in combination with bicalutamide (FB), LE135 (FL) or both NR antagonists (FBL). Stratified responses were observed after the first round of treatment, with combinatorial treatments eliciting modest inhibition of tumor growth. A second round of treatment was administered on day 35, and FBL treatment exhibited the largest treatment response in terms of tumor growth inhibition (Supplementary Figure S7a) . Immunostaining of A431:CAF tumor sections revealed that the combinatorial treatments FL, FB and FBL reduced tumor invasiveness and increased apoptosis, further verified by MMP zymography and immunoblot. FB and FBL treatments inhibited tumor proliferation. (Supplementary Figure  S7b-d) . These findings further demonstrate that CAF-mediated resistance to chemotherapy in SCC can be abrogated by combinatorial treatment with RARβ and AR antagonists, contingent on the profiling of NR expression in CAFs.
DISCUSSION
CAFs are the major cell population within the tumor stroma and are involved in cancer progression. [22] [23] [24] The transcription-based programs underlying the pro-tumor functions of CAFs are not fully understood, and transcription factors are generally considered undruggable. 16, 25 NRs have surfaced as ideal drug targets primarily because their transcriptional activity is precisely modulated by the binding of small lipophilic molecules. 26 The complete NR profile of skin SCC CAFs has not been explored in previous studies. Herein, we showed that among the 48 known human NRs, 18 were upregulated and three were downregulated in SCC CAFs relative to FIBs. To test the functional relevance of individual CAF NRs in SCC malignancy, NRs that were upregulated in SCC CAFs were subjected to siRNA knockdown, whereas downregulated NRs were overexpressed (NR-KD/OECAFs). When NR-KD/OE-CAFs were co-cultured with malignant A-5RT3 SCC cells, the A-5RT3 transcriptome responded to genetic disruption of the CAF NR signature. This highlights a non-cell autonomous effect mediated by an altered paracrine signaling network when CAF NR expression is modified. In particular, we identified RARβ, PPARβ/δ, VDR, GR and AR in CAFs as key players in the attenuation of SCC invasiveness, proliferation, energy metabolism, ROS production and response to chemotherapy. Intriguingly, these same NRs perform critical functions in skin homeostasis, especially during wound healing. 27, 28 As cancers have been described as 'wounds that do not heal', 29, 30 our work strongly suggests that the deregulation of these NRs in FIBs is in part responsible for the manifestation of many pathological skin conditions, including cutaneous SCC. 17 This underscores their tremendous potential as therapeutic targets for a spectrum of skin disorders.
Although the range of chemotherapy options for SCC is increasing, the rapid onset of tumor resistance remains a key challenge for sustained treatment efficacy, especially for conventional chemotherapeutics such as cisplatin. 31 In our in vitro experiments, SCC CAFs doubled the IC 50 of cisplatin in A-5RT3 cells. Chemoresistance in A-5RT3 cells was abrogated by the knockdown of PPARβ/δ, RARβ and VDR in SCC CAF, and CM from CAFs treated with the RARβ antagonist, LE135, and the AR antagonist, bicalutamide, could no longer induce cisplatin resistance in A-5RT3. Notably, our microarray results identified a strong upregulation of HGF, ZEB1, IL6 and POSTN in A-5RT3 cells co-cultured with SCC CAFs. The expression of each of these molecules is associated with the acquisition of resistant phenotypes in various cancers. HGF binding to its receptor, c-MET, triggers the PI3K/Akt and MAPK pathways, which inhibit apoptosis upon chemotherapy challenge.
32 IL6 enacts multidrug resistance via similar intracellular cascades. 33 ZEB1 is a driver of EMT and an inducer of the cancer stem cell phenotype. Post-EMT cells and cancer stem cells are chemorefractory and notoriously difficult to destroy. 34 Finally, POSTN is elevated in the cancer stem cell niche, promotes cancer cell survival and facilitates metastatic colonization. 35 Compatible with the above findings, when RARβ, PPARβ/δ, VDR, GR or AR expression in SCC CAFs was disrupted, the expression of HGF, ZEB1, IL6 and POSTN in A-5RT3 cells was significantly reduced, indicating less chemoresistance. In vivo, concurrent treatments using low-dose cisplatin with LE135 and/or bicalutamide (CL, CB or CBL therapy) resulted in significant A-5RT3:CAF xenograft sensitization to cisplatin compared with cisplatin alone (CV). Tumor relapse upon withdrawal of treatments occurred for all combination therapies tested. However, when treatments were resumed, CV-treated tumors continued to grow. CL therapy inhibited tumor growth and CBL therapy resulted in a near-complete remission of tumors. Importantly, the sustained accumulation of cisplatin adducts in CBL-treated tumors indicated that cisplatin resistance was reduced. Our data illustrate that guided by NR profiling in CAFs, additive or synergistic effects can be achieved when NR ligands are used concurrently with cytotoxic chemotherapy. Nonetheless, we note that our in vivo xenograft experiments involved immune compromised NSG mice, which precludes the influence of tumorassociated immune responses. As immune cells also have an important role in the tumor microenvironment, further studies using immunocompromised mouse models repopulated with matched patient immune cells and patient-derived xenografts are warranted.
Previous CAF-directed treatments have targeted either fibrotic signaling pathways or FIB activation protein activity, with varying success rates. Because CAFs are potent sources of fibroblast growth factor, platelet-derived growth factor and vascular endothelial growth factor, several Phase I/II trials using receptor tyrosine kinase inhibitors that block these signaling pathways are also being conducted. 22 Tranilast, an anti-allergy and antifibrotic drug, is well known to inhibit FIB proliferation and FIB secretion of TGFβ. 36 An in vitro study of mice lymphoma and Lewis lung carcinoma showed that tranilast inhibited CAF-mediated immunosuppression. 37 Another study involving melanoma A375 tumor xenografts in mice showed that tranilast abrogated CAFmediated resistance to radiotherapy. 38 In humans, tranilast yielded promising results in two preliminary clinical studies of prostate cancer. 39, 40 On the other hand, sibrotuzumab, a FIB activation protein-neutralizing antibody, failed to achieve even one complete or partial remission in a phase II trial involving 25 patients with metastatic colon cancer. 41 Another phase II trial with talabostat, a small molecule inhibitor of FIB activation protein, also yielded disappointing patient outcomes. 42 Interestingly, a preclinical study revealed that activation of stromal VDR using calcipotriol increased the efficacy of gemcitabine chemotherapy in a mouse model of pancreatic ductal adenocarcinoma. 43 These studies and ours underscore the importance of developing complementary and combination therapies based on a deeper understanding of CAFs.
MATERIALS AND METHODS
Cell culture
Primary FIBs (ATCC, Manassas, VA, USA) were cultured in FibroGRO-LS (Millipore, Billerica, MA, USA) and used at passage 3-5. SCC CAFs explanted from patient SCC tumors were purchased from Asterand Biosciences (Detroit, MI, USA) and verified for their CAF expression of vimentin and alpha-smooth muscle actin. CAFs were maintained in DMEM supplemented with 5% FBS (Hyclone Laboratories, South Logan, UT, USA). A-5RT3 cells (Heidelberg, German Cancer Research Center) were maintained as previously described. 44 Cell lines were tested to exclude mycoplasma contamination and authenticated against the International Cell Line Authentication Committee (ICLAC) database.
Laser capture microdissection of CAFs
Formalin-fixed, paraffin-embedded skin SCC biopsies from 10 male patients (A-J) were obtained from the National Skin Centre, Singapore. The study was approved by the National Healthcare Group DomainSpecific Review Boards (NHG-DSRB). Microdissection of SCC CAFs and peritumoral FIBs was performed using the PALM MicroBeam (Carl Zeiss, Oberkochen, Germany).
Transfection of CAFs
CAFs were transfected with Dharmafect SMARTpool siRNAs targeting NR transcripts, using DharmaFECT1 (Dharmacon, Lafayette, CO, USA). For NR overexpression, NR genes (Addgene, Cambridge, MA, USA) were delivered to CAFs with the FugeneHD reagent (Promega, Fitchburg, WI, USA).
RNA isolation, RT-qPCR and microarray RNA isolation for RT-qPCR was performed as previously described. 45 ProbeLibrary (Roche Applied Science, Mannheim, Germany) was used to design primers and probes for RT-qPCR (Table 1) . RNA isolation and processing for microarray was performed using the RecoverAll kit (Ambion, Foster City, CA, USA), the Full Spectrum Complete Transcriptome RNA Amplification Kit (System Bioscience, Palo Alto, CA, USA), the Applause WTAmp System (Nugen, San Carlos, CA, USA) and the Encore Biotin Module (Nugen) for loading onto GeneChip Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) chips, according to manufacturer's protocol.
Microarray data analysis
Raw microarray files were imported into Partek Genomic Suite (v6.6) and normalized using robust multiarray averaging. Analysis of variance was performed for all samples with contrast set against the A-5RT3:FIB sample. The 302 genes differentially expressed by 41.5-fold between the A-5RT3: CAF and A-5RT3:FIB samples were examined in all A-5RT3:NR-KD/OE-CAF samples and hierarchically clustered. Ingenuity Pathway Analysis software provided functional annotation of focus molecules. Gene ontology enrichment and top associated networks were assessed based on P-values calculated by the analysis platform.
Invasion, proliferation, glucose uptake and ROS assays A total of 4 × 10 4 A-5RT3 cells and 1.2 × 10 5 FIBs, CAFs or NR-KD/OE-CAFs were seeded in the upper and lower chambers, respectively. The FIBs provided the chemotactic gradient. Invasion assay was performed as previously described, 46 with modification. Invaded A-5RT3 cells on the bottom of the inserts were stained with the infrared dye, SYTO60 (Life Technologies, Camarillo, CA, USA) and quantified with Odyssey CLx (LI-COR Biosciences, Lincoln, NE, USA). Proliferation, glucose uptake and ROS in A-5RT3 cells were assessed as previously described. [47] [48] [49] FACS was performed with the Accuri C6 Flow Cytometer (BD Biosciences, San Diego, CA, USA) and analyzed using FlowJo (Treestar, Ashland, OR, USA).
Energy charge determination
Energy charge in A-5RT3 cells was determined as previously described. 50 Multiple analyte detection MILLIPLEX MAP Human MMP, Human Angiogenesis/Growth Factor and Human Circulating Cancer Biomarker kits were used for multiplexed immunoassay detection of secreted factors in CM (Merck Millipore, Billerica, MA USA). The MAGPIX system was used for data acquisition and analysis was performed with the onboard software (Luminex Corporation, Austin, TX, USA). The concentration of pro-tumor secreted factors in the conditioned media of A-5RT3:CAF and A431:CAF co-cultures treated with LE135, bicalutamide or both were measured by multiplexed immunoassay performed by Eve Technologies (Calgary, Alberta, Canada).
Drug treatments and apoptosis measurements
The 48 h CM (sterile filtered) of FIBs, CAFs and NR-KD/OE-CAFs was added to A-5RT3 cells. In total, 10, 100, 1000, 10000 and 100000 ng/ml of cisplatin (Sigma Aldrich, St Louis, MO, USA) was added to A-5RT3 in CM for 16 h. Apoptosis was measured with Annexin-V and propidium iodide (BioLegend, San Diego, CA, USA) and FACS. IC 50 values were calculated using the graphing software, Prism (GraphPad, CA, USA). Agonists of PPARβ/δ (GW0742), VDR (EB1089) and GR (fluticasone propionate), and antagonists of AR (bicalutamide) and RARβ (LE135) were used at a final concentration of 5 μM (Tocris Bioscience, Bristol, UK). Terminal deoxynucleotidyltransferase dUTP nick end labeling assay (Roche Applied Science) was used for apoptosis measurements in tissue sections.
Animal experiments
Six-week-old male NSG mice (n = 6 per treatment) (Jackson Laboratories, Sacramento, CA, USA) were subcutaneously injected with 2 × 10 5 A-5RT3 cells admixed with 6 × 10 5 CAFs in 50 μl of growth factor-reduced matrigel. Treatments started 3 weeks after tumor xenografts were established (tumor volumes ⩾ 150 mm 3 ). For cisplatin treatment, mice received intraperitoneal or intratumoral injections of 2 mg/kg cisplatin for 2 consecutive weeks. For combination treatments, intraperitoneal injection of 5 mg/kg LE135 and/or 10 mg/kg bicalutamide was administered each time cisplatin was injected. Power analysis was used to determine sample size. Double-blind randomization was used for allocation of the experimental groups. All animal experiments were carried out in accordance to the guidelines of the Institutional Animal Care and Use Committee (ARF-SBS/NIE-A0250AZ, -A0324 and -A0321) of Nanyang Technological University, Singapore.
Immunoblotting and immunostaining
Primary antibodies against mouse and human NRs, PCNA, GLUT1 and β-tubulin (Santa Cruz Biotechnology, Dallas, TX, USA), Ki67 (Dako, Produktionsvej, Glostrup, Denmark), E-cad (Cell Signaling, Danvers, MA, USA) were used. Dye-conjugated secondary antibodies were from LI-COR and Life Technologies. Protein bands were detected using Odyssey CLx (LI-COR Bioscience). Microscopy images were obtained using the LSM710 (Carl Zeiss).
Statistical analysis
Statistical differences were evaluated with two-tailed Mann-Whitney U-test or one-way analysis of variance test with SPSS software where appropriate. P-values o0.05 indicate statistical significance.
